id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-013049-7d436sqg	Sobhanie, Mahdee	Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9)	2016-03-15		.txt	text/plain	4360	214	52	We evaluated a candidate A/Anhui/2013(H7N9) pandemic live attenuated influenza vaccine (pLAIV) in healthy adults, and assessed the ability of 1 or 2 doses to induce immune memory. All subjects received a single 30-µg dose of unadjuvanted, antigenically matched A/Shanghai2/2013(H7N9) pandemic inactivated influenza vaccine (pIIV) 12 weeks after their first dose of pLAIV. Vaccines for control of influenza viruses with pandemic potential are under development, and results of clinical trials have suggested that these vaccines will require the use of adjuvants and multiple doses to induce substantial serum antibody responses [4, 5] . If vaccine virus infection is defined as detection of the virus in culture or by real-time RT-PCR at any time after day 1 or as development of a ≥4-fold increased HAI antibody response, then approximately 20%-30% of subjects were infected after each dose of pLAIV.	./cache/cord-013049-7d436sqg.txt	./txt/cord-013049-7d436sqg.txt